The EPS beat and reaffirmed guidance are positive, but the massive $400M shelf (200% of market cap) and going-concern warning dominate the risk profile. The SENTRY trial's mixed results (met spleen endpoint, missed symptom endpoint) create binary ASCO catalyst risk on June 2. The cash runway into late Q3 2026 forces a near-term capital raise, likely highly dilutive. Traders should watch for the ASCO presentation on June 2 and any pre-announcement of financing terms.
KPTI drugs
KPTI drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 14 $8.90entry
- T+1 · 6mo ago −13.82%α −12.59% · $7.67
- T+5 · 6mo ago −9.44%α −8.72% · $8.06
- T+20 · 5mo ago +6.74%α +7.60% · $9.50
- T+60 · due 3mo ago Pending
Price Chart
How similar events traded
Executive Summary
Karyopharm reported Q1 2026 total revenue of $35.1M (up 17% YoY) and a net loss of $22.4M ($1.02 per basic share), beating consensus EPS of -$1.44 by 29%. The company reaffirmed full-year 2026 revenue guidance of $130M-$150M and completed enrollment in the Phase 3 XPORT-EC-042 endometrial cancer trial. However, the Phase 3 SENTRY myelofibrosis trial missed its second co-primary endpoint (symptom score), and a $400M shelf registration filed 10 days ago (including a $100M ATM) represents massive potential dilution (~200% of market cap) with a going-concern warning. The cash runway extends only into late Q3 2026, creating acute financing risk.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $35.1M vs $30.0M YoY (+17%); net product revenue $29.2M vs $21.1M YoY (+38%)
- Net loss $22.4M ($1.02 basic share) vs consensus EPS -$1.44, a 29% beat
- Full-year 2026 guidance reaffirmed: total revenue $130M-$150M, XPOVIO net product revenue $115M-$130M
- Phase 3 SENTRY myelofibrosis trial met SVR35 endpoint but missed Abs-TSS symptom score co-primary endpoint
- Phase 3 XPORT-EC-042 endometrial cancer trial enrollment completed (n=257); topline data expected mid-2026
- Cash $91.2M as of March 31, 2026, including ~$50M from Q1 2026 financing; runway only into late Q3 2026
- $400M universal shelf registration (including $100M ATM) filed May 4, 2026, ~200% of market cap
- Auditor raised substantial doubt about going concern; massive potential dilution ahead
Financial Impact
Q1 2026 revenue $35.1M (+17% YoY); net loss $22.4M improved from $23.5M YoY; cash burn ~$9M/month; $400M shelf overhang
Risk Factors
- Massive dilution from $400M shelf registration (~200% of market cap), likely near-term capital raise
- Going-concern warning with cash runway only into late Q3 2026
- SENTRY trial missed symptom endpoint, ASCO presentation on June 2 could disappoint
- XPOVIO demand declining due to new competitive entrants in multiple myeloma
- High debt load ($224M in convertible notes + $120M secured term loan + $72M deferred royalty)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-222808 |
| Document: kpti-20260514.htm | 0001193125-26-222808 |
| Document: 0001193125-26-222808-index-headers.html | 0001193125-26-222808 |
| Document: 0001193125-26-222808-index.html | 0001193125-26-222808 |
| Document: 0001193125-26-222808.txt | 0001193125-26-222808 |
| 8-K Data (Synthetic) | 0001193125-26-222808 |
Track record
30 reports on KPTI
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers